Table 2.

Clinical characteristics of patients with MF who responded to CEP-701

Patient no.	Sex/age, y	Prior treatment	Hemoglobin (g/dL)	WBC (× 109/L)	Platelets (× 109/L)	Spleen, cm	JAK2V617F allele burden, percentage	Karyotype	Cycles to response, mo	Response and response duration, mo
1	Female/61	Hydroxyurea, anagrelide	13.3	39.2	457	9	94.5	Diploid	3	CI (spleen) 3+
2	Male/59	Erythropoietin	8.9*	3.8	66	0	42.1	Insufficient yield	1	CI (hemoglobin) 22+
3	Male/56	Lenalidomide	13	19.7	223	13	68.7	46, XY, del 13(q12;q22)[3]	3	CI (spleen) 19+
4	Female/70	IFN, thalidomide, lenalidomide, erythropoietin, prednisone	10	14.9	70	21	40.2	46, X, t(X;1)(q11;p31), del(13)(q12q22)[11]; 46,XX,del(20) (q11q13)[9]	4	CI (spleen) 5
5	Female/71	Chlorambucil, hydroxyurea, thalidomide, lenalidomide, anagrelide, erythropoietin	8.4*	1.6	22	10	30	46,XX,del(4) (q21q33) [7]; 46,X,del(X) (q22q28) [6]; 46,XX,add(3) (q27), del(3) (q21q26.2), del(5) (q31q35), del(6) (p21p23), add(20) (q13) [2]; 46,XX,del(2) (p11p25) [1]	1	CI (absolute neutrophil count, spleen, platelets) 14
6	Male/60	Hydroxyurea, anagrelide, darbepoietin	9.5*	11.7	216	0	72.2	Diploid	9	CI (hemoglobin) 12

CI indicates clinical improvement.

^*Patients were transfusion-dependent.